Equities research analysts forecast that Amedisys Inc (NASDAQ:AMED) will post $403.62 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Amedisys’ earnings. The lowest sales estimate is $398.38 million and the highest is $407.00 million. Amedisys reported sales of $378.82 million during the same quarter last year, which indicates a positive year over year growth rate of 6.5%. The business is expected to report its next earnings report on Wednesday, July 25th.
According to Zacks, analysts expect that Amedisys will report full year sales of $1.63 billion for the current financial year, with estimates ranging from $1.61 billion to $1.64 billion. For the next year, analysts anticipate that the firm will report sales of $1.73 billion per share, with estimates ranging from $1.68 billion to $1.75 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Amedisys.
Amedisys (NASDAQ:AMED) last posted its earnings results on Monday, May 7th. The health services provider reported $0.79 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.67 by $0.12. Amedisys had a return on equity of 16.83% and a net margin of 2.71%. The firm had revenue of $399.30 million for the quarter, compared to analyst estimates of $395.38 million. During the same quarter in the prior year, the company earned $0.47 EPS. Amedisys’s revenue was up 9.5% on a year-over-year basis.
Several research firms recently issued reports on AMED. BidaskClub lowered Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 18th. Bank of America increased their target price on Amedisys from $73.00 to $78.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 5th. Stephens reissued a “hold” rating and set a $78.00 target price on shares of Amedisys in a research note on Tuesday, June 5th. Robert W. Baird increased their target price on Amedisys from $67.00 to $72.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 5th. Finally, Craig Hallum increased their target price on Amedisys from $60.00 to $82.00 and gave the stock a “buy” rating in a research note on Wednesday, May 9th. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $70.55.
In other Amedisys news, Director Jake L. Netterville sold 4,096 shares of the stock in a transaction dated Tuesday, June 12th. The stock was sold at an average price of $80.44, for a total value of $329,482.24. Following the sale, the director now owns 77,660 shares of the company’s stock, valued at approximately $6,246,970.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Scott G. Ginn sold 7,755 shares of the stock in a transaction dated Thursday, June 7th. The shares were sold at an average price of $78.44, for a total value of $608,302.20. The disclosure for this sale can be found here. Insiders sold a total of 2,467,803 shares of company stock worth $182,590,696 in the last ninety days. 2.60% of the stock is owned by corporate insiders.
Hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new stake in Amedisys in the 1st quarter valued at about $123,000. Mount Yale Investment Advisors LLC acquired a new stake in shares of Amedisys during the 1st quarter worth about $151,000. Xact Kapitalforvaltning AB acquired a new stake in shares of Amedisys during the 1st quarter worth about $257,000. Paloma Partners Management Co acquired a new stake in shares of Amedisys during the 4th quarter worth about $310,000. Finally, Stone Ridge Asset Management LLC acquired a new stake in shares of Amedisys during the 4th quarter worth about $364,000. 93.74% of the stock is currently owned by institutional investors.
Amedisys opened at $85.46 on Thursday, according to MarketBeat. Amedisys has a 12-month low of $45.60 and a 12-month high of $88.60. The company has a current ratio of 1.63, a quick ratio of 1.63 and a debt-to-equity ratio of 0.14. The stock has a market cap of $2.91 billion, a P/E ratio of 33.78, a PEG ratio of 1.48 and a beta of 0.64.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Get a free copy of the Zacks research report on Amedisys (AMED)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.